Core Viewpoint - The report from First Shanghai gives a "buy" rating for Cloud Factory (02512), with a target price of HKD 6.9, indicating a 36% upside potential from the current price, driven by the company's strategic positioning in new business areas and alignment with government policies on "Artificial Intelligence+" [1] Financial Performance - In H1 2025, the group's total revenue reached HKD 406.8 million, a year-on-year increase of 10.0%, primarily due to regular business expansion and significant growth in edge computing services [1] - Gross profit was HKD 47.7 million, with an overall gross margin of 11.7%, while net profit stood at HKD 14.9 million, reflecting a year-on-year growth of 19.0% [1] - The earnings per share for ordinary equity holders remained at HKD 0.03, and as of June 30, the group had cash and cash equivalents of HKD 348.1 million, indicating strong liquidity reserves [1] IDC Solutions Growth - The revenue from IDC solutions services in H1 2025 reached HKD 376.1 million, a year-on-year increase of 7.9%, accounting for 92.5% of total revenue [2] - The growth in revenue was attributed to the company's strong reputation, stable customer base, and extensive business network, despite a decrease in gross margin to 10.2% due to competitive pricing strategies [2] Edge Computing Services - Revenue from edge computing services grew to HKD 29.2 million, a year-on-year increase of 39.0%, representing 7.2% of total revenue, driven by increased market demand for EdgeCDN services and new customer acquisition [3] - The gross margin for this segment was 27.1%, and the company has been recognized as one of the top 20 edge computing companies in China for three consecutive years [3] Strategic Development - The company focuses on four strategic areas: expanding smart computing services, enhancing technology research and development, strengthening ecosystem partnerships, and building a dual-driven model for government and enterprise solutions [4] - Recent capital raised from new share subscriptions will be used for various business developments, including the establishment of a joint venture to explore the smart computing services market [4]

Core Viewpoint - The report maintains a "Buy" rating for China National Pharmaceutical Group (国药控股) with a target price of HKD 21.3, highlighting short-term performance pressure but long-term benefits from aging trends and policy integration [1] Financial Performance - In H1 2025, the company reported revenue of CNY 286.04 billion, a decrease of 2.95% year-on-year, with a gross profit of CNY 20.35 billion, down 7.28% [1] - The overall gross margin was under pressure at 7.11%, a decline of 0.34% year-on-year, while net profit fell to CNY 5.337 billion, down 9.53% [1] - Profit attributable to equity holders was CNY 3.47 billion, a decrease of 6.43%, but effective cost control led to a reduction in selling, administrative, and financial expense ratios [1] Pharmaceutical Distribution Segment - The pharmaceutical distribution segment generated revenue of CNY 218.53 billion, down 3.52% year-on-year, with an operating profit margin of 2.58%, a decline of 0.17 percentage points [2] - The company is focusing on core hospital markets and grassroots medical needs, which has contributed to overall market share growth despite revenue decline [2] - The strategic shift to reduce low-margin revenue has improved supply chain efficiency and compliance [2] Medical Device Distribution - Revenue from the medical device distribution business was CNY 57.05 billion, down 2.46%, with an operating profit margin of 1.92%, a decrease of 0.33 percentage points [2] - The company is optimizing channel structures and has added new projects to enhance revenue, with SPD projects driving a 13% year-on-year increase in device revenue [2] Retail Pharmacy Segment - The retail pharmacy segment achieved revenue of CNY 17.16 billion, a growth of 3.6%, with an operating profit margin of 2.68%, up 1.13 percentage points [3] - As of June 30, 2025, the total number of Guoda pharmacies was 8,591, a net decrease of 978 stores, focusing on quality improvement and network optimization [3] - The net profit of the retail segment saw a significant increase of 215.8% year-on-year, driven by same-store sales growth in prescription and innovative drug support [3]

Core Viewpoint - The report maintains a "Buy" rating for China National Pharmaceutical Group (国药控股) with a target price of HKD 21.3, highlighting short-term performance pressure but long-term benefits from aging trends and policy integration [1] Financial Performance - In the first half of 2025, the company achieved revenue of CNY 286.04 billion, a decrease of 2.95% year-on-year, with a gross profit of CNY 20.35 billion, down 7.28% [1] - The overall gross margin continued to be under pressure at 7.11%, a decline of 0.34% year-on-year, while net profit was CNY 5.337 billion, down 9.53% [1] - Profit attributable to equity holders was CNY 3.47 billion, a decrease of 6.43% year-on-year, with effective cost control leading to reduced expense ratios [1] Pharmaceutical Distribution Segment - Revenue for the pharmaceutical distribution segment was CNY 218.53 billion, down 3.52% year-on-year, with an operating profit margin of 2.58%, a decline of 0.17 percentage points [2] - The company is focusing on core hospital markets and grassroots medical needs, which has contributed to overall market share growth despite revenue decline [2] - The strategic shift to reduce low-margin revenue has improved supply chain efficiency and compliance [2] Medical Device Distribution - Revenue from medical device distribution was CNY 57.05 billion, down 2.46% year-on-year, with an operating profit margin of 1.92%, a decrease of 0.33 percentage points [2] - The company is optimizing channel structures and has added new projects to enhance revenue, with SPD projects driving a 13% year-on-year increase in device revenue [2] Retail Pharmacy Segment - The retail pharmacy segment achieved revenue of CNY 17.16 billion, a growth of 3.6% year-on-year, with an operating profit margin of 2.68%, an increase of 1.13 percentage points [3] - As of June 30, 2025, the total number of Guoda pharmacies was 8,591, a net decrease of 978 stores, focusing on quality improvement and network optimization [3] - The professional pharmacy segment saw a reduction in store numbers but maintained double-digit same-store revenue growth due to supportive policies [3]

Core Viewpoint - The latest data from the Hong Kong Stock Exchange indicates significant shareholder activity in 康达环保 (Kangda Environmental), with a notable portion of shares deposited with First Shanghai Securities, reflecting ongoing interest in the company's stock [1] Group 1: Shareholder Activity - On September 26, 康达环保's shareholders deposited shares worth HKD 60.7284 million with First Shanghai Securities, representing 6.93% of the company's total shares [1] - As of September 22, 康达环保, along with China Water Affairs and the joint offeror, announced that the offer would close on September 22, 2025, with no further amendments or extensions planned [1] Group 2: Offer Acceptance - By the closing time of the offer on September 22, 2025, the joint offeror received valid acceptances for a total of 335 million shares, which accounts for approximately 14.53% of the company's total issued share capital as of the announcement date [1] - Additionally, there were valid acceptances for 44.2 million stock options, representing about 26.7% of the stock options offered [1]

Group 1 - The core point of the article highlights that on September 26, shareholders of 康达环保 (Kangda Environmental) deposited shares worth HKD 60.7284 million into First Shanghai Securities, representing 6.93% of the total [1] - On September 22, 康达环保, China Water Affairs, and the joint offeror announced that the offer would close at 4 PM on September 22, 2025, with no further amendments or extensions made by the joint offeror [1] - As of the deadline, the joint offeror received valid acceptances for a total of 335 million shares under the share offer, accounting for approximately 14.53% of the total issued share capital of the company as of the announcement date [1] Group 2 - Additionally, under the share option offer, a total of 44.2 million share options were validly accepted, representing about 26.7% of the share options available under the offer [1]

Group 1 - The core point of the article highlights the recent stock transfer of New Ji'ao RV (00805) from First Shanghai Securities to Shengheng Financial Holdings, with a market value of HKD 61.0351 million, representing 5.34% of the total shares [1] - New Ji'ao RV reported its mid-year results for 2025, showing a revenue of approximately HKD 412 million, a year-on-year decrease of 2.4% [1] - The company's gross profit was about HKD 122 million, reflecting a year-on-year decline of 9.9% [1] - The profit attributable to equity shareholders was HKD 30.7 million, down 22.34% compared to the previous year [1] - Earnings per share stood at HKD 0.03 [1]

Core Viewpoint - New Giao RV (00805) has experienced a shareholder transfer and reported a decline in financial performance for the first half of 2025 [1] Group 1: Shareholder Activity - On September 23, New Giao RV's shares were transferred from First Shanghai Securities to Shengheng Financial Holdings, with a market value of HKD 61.0351 million, representing 5.34% of the total shares [1] Group 2: Financial Performance - For the first half of 2025, New Giao RV reported revenue of approximately HKD 412 million, a year-on-year decrease of 2.4% [1] - The gross profit was approximately HKD 122 million, reflecting a year-on-year decline of 9.9% [1] - The profit attributable to equity shareholders was HKD 30.7 million, down 22.34% year-on-year, with earnings per share of HKD 0.03 [1]

Company Overview - The company primarily engages in financial services and real estate development and investment, operating through five segments: financial services, property development, property investment and hotel operations, healthcare, and direct investments [11]. Financial Performance - In the first half of 2025, the company's average return on equity was 0.13%, a decrease of 2.65 percentage points compared to the same period last year [20]. - The net cash flow from operating activities for the first half of 2025 was HKD 167 million, while cash flow from financing activities was negative HKD 25.615 million, and cash flow from investing activities was negative HKD 3.389 million [24]. - The company's revenue and net profit growth rates showed fluctuations over the years, with significant changes noted in 2023 and 2024 [14][15]. Revenue Composition - In the first half of 2025, the revenue composition was as follows: financial services contributed HKD 1.101 billion, property investment and hotel operations contributed HKD 1.514 billion, and property development contributed HKD 0.117 billion [15][17]. Asset and Liability Changes - As of the first half of 2025, the company's cash and cash equivalents increased by 43.52%, accounting for a 9.92 percentage point rise in total assets [32]. - The company's accounts payable and notes payable increased by 31.26%, representing a 6.36 percentage point rise in total assets [35]. - The company's liquidity ratios were reported as follows: current ratio at 1.48 and quick ratio at 1.38 [38]. Historical Trends - The company's historical asset turnover ratio and fixed asset turnover ratio showed a downward trend, with the asset turnover ratio at 0.08 times in the first half of 2025 [28][29]. - The historical debt-to-asset ratio has been fluctuating, with the latest figure indicating a decrease in comparison to previous years [37].

FIRST SHANGHAI INVESTMENTS LIMITED 第一上海投資有限公司 (Incorporated in Hong Kong with limited liability) Dear non-registered shareholder(s), 23 September 2025 First Shanghai Investments Limited (the "Company") – 2025 Interim Report (the "Current Corporate Communication") We are pleased to inform you that the English and Chinese versions of the Current Corporate Communication are now available on the HKEXnews website at www.hkexnews.hk and on the Company's website at www.firstshanghai.com.hk. You may access the Curr ...

Collection of your Electronic Contact Details FIRST SHANGHAI INVESTMENTS LIMITED 第一上海投資有限公司 (Incorporated in Hong Kong with limited liability) ( 於香港註冊成立之有限公司 ) (Stock Code 股份代號： 227) Dear registered shareholder(s), First Shanghai Investments Limited (the "Company") – 2025 Interim Report (the "Current Corporate Communication") We are pleased to inform you that the English and Chinese versions of the Current Corporate Communication are now available o n the HKEXnews website at www.hkexnews.hk and on the Compa ...